Wall Street brokerages expect that Repligen Co. (NASDAQ:RGEN) will report earnings per share of $0.21 for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Repligen’s earnings. The highest EPS estimate is $0.22 and the lowest is $0.18. Repligen posted earnings per share of $0.20 in the same quarter last year, which would indicate a positive year-over-year growth rate of 5%. The company is scheduled to report its next earnings report on Thursday, November 7th.
On average, analysts expect that Repligen will report full year earnings of $0.97 per share for the current year, with EPS estimates ranging from $0.94 to $1.00. For the next financial year, analysts anticipate that the business will report earnings of $1.13 per share, with EPS estimates ranging from $1.11 to $1.15. Zacks’ EPS averages are an average based on a survey of sell-side research firms that cover Repligen.
Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. Repligen had a return on equity of 7.66% and a net margin of 11.42%. The business had revenue of $70.70 million during the quarter, compared to the consensus estimate of $65.47 million. During the same period last year, the company earned $0.14 EPS. The company’s revenue for the quarter was up 48.1% on a year-over-year basis.
A number of brokerages have issued reports on RGEN. ValuEngine downgraded Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research raised Repligen from a “hold” rating to a “strong-buy” rating and set a $102.00 target price for the company in a research note on Thursday, July 18th. BidaskClub raised Repligen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 27th. Finally, HC Wainwright raised Repligen from a “neutral” rating to a “buy” rating and set a $110.00 target price for the company in a research note on Monday, July 22nd. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Repligen has an average rating of “Buy” and an average target price of $94.00.
Shares of RGEN traded down $4.90 during midday trading on Friday, reaching $90.61. The company had a trading volume of 1,491,723 shares, compared to its average volume of 636,756. Repligen has a 1-year low of $47.23 and a 1-year high of $99.25. The company has a market capitalization of $4.51 billion, a PE ratio of 124.12, a PEG ratio of 5.74 and a beta of 1.08. The business has a 50 day simple moving average of $85.77. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.84 and a current ratio of 2.18.
In related news, Director Glenn L. Md Cooper sold 5,000 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $66.94, for a total transaction of $334,700.00. Following the completion of the sale, the director now directly owns 35,975 shares of the company’s stock, valued at approximately $2,408,166.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karen A. Dawes sold 1,295 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $77.35, for a total value of $100,168.25. Following the sale, the director now directly owns 118,329 shares of the company’s stock, valued at $9,152,748.15. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by company insiders.
Several large investors have recently modified their holdings of the stock. Huntington National Bank acquired a new position in Repligen in the 1st quarter valued at about $25,000. Royce & Associates LP grew its position in Repligen by 40.6% in the 1st quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 145 shares in the last quarter. Mascoma Wealth Management LLC acquired a new position in Repligen in the 1st quarter valued at about $41,000. Private Capital Group LLC grew its position in Repligen by 675.3% in the 1st quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 628 shares in the last quarter. Finally, South Dakota Investment Council acquired a new position in Repligen in the 1st quarter valued at about $83,000. 85.56% of the stock is owned by hedge funds and other institutional investors.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Further Reading: What does a neutral rating on stocks mean?
Get a free copy of the Zacks research report on Repligen (RGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.